RxDoctor Payments Data

Nikki Zybach

Physician Assistant · Oklahoma City, OKNPI 1457565988

Payments from drug & device makers

$7,365in general payments, 2019–2025

Across 466 payments — averaging $15.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$1K
  • Pfizer$454
  • Lilly USA, LLC$449
  • AstraZeneca$434
  • Antares Pharma, Inc.$405
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$7,27099%
  • Education$951%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,365 in reported general payments places this provider in the 95th percentile of 1,491 physician assistant providers in Oklahoma.

See all physician assistant providers in Oklahoma

Medicare billing

Part B allowed, 2024
$10,204
Medicare patients
58
Services billed
586

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide52$64,831
MounjaroTirzepatide46$61,776
TrulicityDulaglutide22$38,555
JardianceEmpagliflozin19$24,207
RybelsusSemaglutide18$20,346
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$18,240
FarxigaDapagliflozin Propanediol19$17,301
EliquisApixaban13$9,782
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$3,593
Humalog Kwikpen U-100Insulin Lispro11$2,991
Albuterol Sulfate HfaAlbuterol Sulfate70$2,216
Celecoxib36$1,815
Rosuvastatin Calcium119$1,567
Omeprazole74$1,438
Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet16$1,281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$449$100,33168 claims
Novo NordiskOzempic, Rybelsus$1,050$85,17670 claims
Boehringer IngelheimJardiance$252$24,20719 claims
GSKTrelegy Ellipta$176$18,24017 claims
AstraZenecaFarxiga$434$17,30119 claims
PfizerEliquis$454$9,78213 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$14$936140 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,491 physician assistant providers in Oklahoma.

Other physician assistant in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →